The Patent Finder

Targeted Binding Agents Against B7-H1

MedImmune, LLC

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 5 of these applications claim priority to application PCT/US2010/058007, filed Nov 24, 2010. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 8,779,108Targeted Binding Agents Against B7-H1
In force
 · High confidence
MedImmune LimitedIn force
High confidence
US 10,400,039Targeted Binding Agents Against B7-H1
In force
 · Medium confidence
MedImmune LimitedIn force
Medium confidence
US 11,518,809Targeted Binding Agents Against B7-H1
In force
 · Medium confidence
MedImmune LimitedIn force
Medium confidence
US 9,493,565Targeted Binding Agents Against B7-H1
In force
 · Medium confidence
MedImmune LimitedIn force
Medium confidence
US 12,686,718Targeted Binding Agents Against B7-H1
In force
 · Medium confidence
MedImmune LimitedIn force
Medium confidence
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited